Search results for "uterine leiomyoma"

showing 10 items of 21 documents

Molecular differential diagnosis of uterine leiomyomas and leiomyosarcomas.

2018

Abstract Uterine leiomyomas (LM) and leiomyosarcomas (LMS) are considered biologically unrelated tumors due to their cytogenetic and molecular disparity. Yet, these tumors share morphological and molecular characteristics that cannot be differentiated through current clinical diagnostic tests, and thus cannot be definitively classified as benign or malignant until surgery. Newer approaches are needed for the identification of these tumors, as has been done for other tissues. The application of next generation sequencing enables the detection of new mutations that, when coupled to machine learning bioinformatic tools, advances our understanding of chromosomal instability. These approaches in…

0301 basic medicineLeiomyosarcomaContext (language use)BiologyBioinformaticsDNA sequencingCirculating Tumor DNADiagnosis Differential03 medical and health sciences0302 clinical medicineCirculating tumor cellChromosome instabilityHumansPrecision Medicine030219 obstetrics & reproductive medicineUterine leiomyomaLeiomyomaLiquid BiopsyBiologically UnrelatedHigh-Throughput Nucleotide SequencingCell BiologyGeneral Medicine030104 developmental biologyReproductive MedicineMolecular Diagnostic TechniquesMutationUterine NeoplasmsIdentification (biology)FemaleDifferential diagnosisBiology of reproduction
researchProduct

Long-term vitamin D treatment decreases human uterine leiomyoma size in a xenograft animal model

2019

Objective To study the effects of short- and long-term vitamin D treatment on uterine leiomyomas in vivo through cell proliferation, extracellular matrix (ECM) degradation, and apoptosis. Design Preclinical study of human leiomyoma treatment with vitamin D in an nonhuman animal model. Setting Hospital and university laboratories. Patient(s)/Animal(s) Human leiomyomas were collected from patients and implanted in ovariectomized NOD-SCID mice. Intervention(s) Mice were treated with vitamin D (0.5 μg/kg/d or 1 μg/kg/d) or vehicle for 21 or 60 days. Main Outcome Measure(s) Vitamin D effect in xenograft tissue was assessed by monitoring tumor size (18F-FDG positron-emission tomography/computeriz…

0301 basic medicineVitaminmedicine.medical_specialtyMice SCIDDrug Administration ScheduleMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMice Inbred NODPositron Emission Tomography Computed TomographyInternal medicinemedicineVitamin D and neurologyAnimalsHumansVitamin DCell Proliferation030219 obstetrics & reproductive medicineUterine leiomyomaLeiomyomabusiness.industryObstetrics and Gynecologymedicine.diseaseXenograft Model Antitumor AssaysTumor BurdenBlotTreatment Outcome030104 developmental biologyLeiomyomaEndocrinologyReproductive MedicinechemistryApoptosisPlasminogen activator inhibitor-1Ovariectomized ratFemalebusinessFertility and Sterility
researchProduct

Inhibition of tumor cell proliferation in human uterine leiomyomas by vitamin D via Wnt/β-catenin pathway.

2018

To assess the effect of vitamin D (VitD) on human uterine leiomyomas through Wnt/β-catenin pathway inhibition, apoptosis induction, and cell growth arrest.A prospective study comparing leiomyoma vs. myometrium tissues. Paired design study comparing human uterine leiomyoma primary (HULP) cells treated with or without VitD.University hospital.Human uterine leiomyoma and myometrium were collected from women (aged 35-52 years) without hormonal treatment.Samples were collected from women undergoing surgery due to symptomatic uterine leiomyoma pathology.Uterine leiomyoma and myometrium tissues were analyzed by western blot (WB) to determine proliferation, Wnt/β-catenin, and apoptosis pathways. HU…

AdultAntineoplastic AgentsApoptosisTumor Cells CulturedMedicineHumansVitamin DWnt Signaling PathwayCell ProliferationUterine leiomyomaLeiomyomabusiness.industryCell growthWnt signaling pathwayMyometriumObstetrics and GynecologyCell cycleMiddle Agedmusculoskeletal systemmedicine.diseasefemale genital diseases and pregnancy complicationsGene Expression Regulation NeoplasticLeiomyomaReproductive MedicineApoptosisCateninUterine NeoplasmsCancer researchFemalebusinessApoptosis Regulatory ProteinsFertility and sterility
researchProduct

Histone deacetylase inhibition by suberoylanilide hydroxamic acid: a therapeutic approach to treat human uterine leiomyoma.

2022

Objective To evaluate the effect of inhibition of histone deacetylases (HDACs) by suberoylanilide hydroxamic acid (SAHA) treatment of human uterine leiomyoma primary (HULP) cells in vitro on cell proliferation, cell cycle, extracellular matrix (ECM) formation, and transforming growth factor β3 (TGF-β3) signaling. Design Prospective study comparing uterine leiomyoma (UL) vs. adjacent myometrium (MM) tissue and cells with or without SAHA treatment. Setting Hospital and university laboratories. Patient(s) Women with UL without any hormone treatment. Intervention(s) Myomectomy or hysterectomy surgery in women for leiomyoma disease. Main Outcome Measure(s) HDAC activity was assessed by enzyme-li…

AdultAntineoplastic AgentsHistone Deacetylase 1MMP9Histone Deacetylase 6Histone DeacetylasesCyclin D1Transforming Growth Factor beta3Cell proliferation SAHA ULS-ß3 pathway extracellular matrix uterine leiomyomaTumor Cells CulturedHumansViability assayProspective StudiesCell ProliferationVorinostatbiologyLeiomyomaChemistryCell growthCell CycleObstetrics and GynecologyCell cycleMiddle AgedHDAC3Molecular biologyProliferating cell nuclear antigenExtracellular MatrixGene Expression Regulation NeoplasticHistone Deacetylase InhibitorsReproductive MedicineUterine Neoplasmsbiology.proteinFemaleHistone deacetylaseSignal TransductionFertility and sterility
researchProduct

Lack of Hypoxic Response in Uterine Leiomyomas despite Severe Tissue Hypoxia

2008

Abstract Hypoxia is now established as a key factor influencing the pathophysiology of malignant growth. Among other effects, hypoxia modulates the expression of a multitude of genes through the induction of hypoxia-inducible transcription factors. This differential gene expression favors angiogenesis, cell survival, an invasive/metastatic phenotype, and resistance to anticancer therapies. Because benign tumors do not exhibit these traits, one might expect these entities to be neither hypoxic nor to induce the genetic hypoxia response program. To test this hypothesis, an investigation of the oxygenation status of 17 leiomyomas and 1 leiomyosarcoma of the uterus using polarographic needle el…

AdultLeiomyosarcomaLeiomyosarcomaCancer ResearchPathologymedicine.medical_specialtyAngiogenesisUterusUterine Cervical NeoplasmsApoptosisBiologyImmunoenzyme TechniquesAntigens NeoplasmBiopsyBasic Helix-Loop-Helix Transcription FactorsIn Situ Nick-End LabelingmedicineHumansProspective StudiesCarbonic Anhydrase IXHypoxiaCarbonic AnhydrasesCell ProliferationGlucose Transporter Type 1Uterine leiomyomaLeiomyomamedicine.diagnostic_testMiddle AgedHypoxia (medical)Hypoxia-Inducible Factor 1 alpha Subunitmedicine.diseasePhenotypeOxygenmedicine.anatomical_structureLeiomyomaOncologyMyometriumFemalemedicine.symptomCancer Research
researchProduct

Vitamin D as an effective treatment in human uterine leiomyomas independent of mediator complex subunit 12 mutation.

2021

Objective To study whether vitamin D (VitD) inhibits cell proliferation and Wnt/β-catenin and transforming growth factor−β (TGFβ) signaling pathways in uterine leiomyomas independent of mediator complex subunit 12 (MED12) mutation status. Design Prospective study comparing leiomyoma vs. myometrial tissues and human uterine leiomyoma primary (HULP) cells treated with or without VitD and analyzed by MED12 mutation status. Setting Hospital and university laboratories. Patient(s) Women with uterine leiomyoma without any treatment (n = 37). Intervention(s) Uterine leiomyoma and myometrium samples were collected from women undergoing surgery because of symptomatic leiomyoma pathology. Main Outcom…

AdultMMP9MED12AndrologyWNT4medicineVitamin D and neurologyHumansProspective StudiesVitamin DneoplasmsCells CulturedCell ProliferationUterine leiomyomaMediator ComplexLeiomyomabusiness.industryWnt signaling pathwayMyometriumObstetrics and GynecologyMiddle Agedmusculoskeletal systemmedicine.diseasefemale genital diseases and pregnancy complicationsLeiomyomaTreatment OutcomeReproductive MedicineMutationUterine NeoplasmsFemalebusinessFertility and sterility
researchProduct

Uterine leiomyoma metastasis as a first sign of breast cancer

1998

Uterine metastases from extragenital cancer are rarely reported in the literature. More frequently, the female genital tract is involved by direct extension from an adjacent pelvic organ. A 37-year-old woman had a myoma of the uterine wall and hypermenorrhea. The mass was laparoscopically enucleated, and frozen section examination was performed because it was macroscopically suspicious for sarcomatoid degeneration. The final diagnosis was metastatic carcinoma in the uterus of probable breast origin.

Adultmedicine.medical_specialtyPathologyUterusAntineoplastic AgentsBreast NeoplasmsMetastatic carcinomaMetastasisFatal OutcomeBreast cancermedicineHumansGynecologyFrozen section procedureUterine leiomyomaLeiomyomabusiness.industryBiopsy NeedleObstetrics and GynecologyCancerMyomamedicine.diseaseImmunohistochemistrymedicine.anatomical_structureChemotherapy AdjuvantLymphatic MetastasisUterine NeoplasmsFemaleLaparoscopyRadiotherapy AdjuvantbusinessThe Journal of the American Association of Gynecologic Laparoscopists
researchProduct

Ulipristal acetate versus leuprolide acetate for uterine fibroids

2012

A b s t r ac t Background The efficacy and side-effect profile of ulipristal acetate as compared with those of leuprolide acetate for the treatment of symptomatic uterine fibroids before surgery are unclear. Methods In this double-blind noninferiority trial, we randomly assigned 307 patients with symptomatic fibroids and excessive uterine bleeding to receive 3 months of daily therapy with oral ulipristal acetate (at a dose of either 5 mg or 10 mg) or once-monthly intramuscular injections of leuprolide acetate (at a dose of 3.75 mg). The primary outcome was the proportion of patients with controlled bleeding at week 13, with a prespecified noninferiority margin of −20%. Results Uterine bleed…

Adultmedicine.medical_specialtyUterine fibroidsIntention to Treat AnalysiUrologyAdministration OralEndometriumInjections Intramuscularlaw.inventionchemistry.chemical_compoundYoung AdultEndometriumPrimary outcomeRandomized controlled trialDouble-Blind MethodlawUlipristal acetateSelective progesterone receptor modulatormedicineUterine NeoplasmUlipristalMenorrhagiaGynecologyIntention-to-treat analysisLeiomyomabusiness.industryObstetrics and GynecologyUterine bleedingUterine fibroids uterine leiomyomas uterine bleeding ulipristal acetate leuprolide acetate medical therapyGeneral MedicineNorpregnadieneMiddle Agedmedicine.diseaseSettore MED/40 - Ginecologia E Ostetriciamedicine.anatomical_structurechemistryAmenorrheaFemalemedicine.symptomLeuprolidebusinessHuman
researchProduct

Peritoneal sarcomatosis 5 years after laparoscopic morcellation of uterine leiomyoma.

2017

In 2011, a 40-year-old woman underwent laparoscopic myomectomy with intraabdominal morcellation. Histology report showed leiomyoma without atypia, necrosis, or mitosis. In 2016, she complained of left lower quadrant pain; ultrasound examination revealed a left hypogastric mass in the site of trocar placement. Percutaneous biopsy results showed a low-grade endometrial stromal sarcoma (LGESS). At laparoscopy, we observed: multiple nodules on uterine serosa, left annex, vesical peritoneum (Figure 1), Douglas pouch (Supplementary Video1), previous left pelvic trocar site (Figure 2), greater omentum (Figure 3), and right/left diaphragm.

Adultmedicine.medical_specialtymedicine.medical_treatmentSarcoma Endometrial StromalMorcellationAnastomosisHysterectomyDouglas' Pouch03 medical and health sciences0302 clinical medicineUterine MyomectomyUterine NeoplasmmedicineHumansEndometrial Neoplasm030212 general & internal medicinePeritoneal Neoplasms030219 obstetrics & reproductive medicineUterine leiomyomaHysterectomyLeiomyomabusiness.industryAnastomosis SurgicalRectumObstetrics and GynecologySarcomatosismedicine.diseaseUterine myomectomySurgeryEndometrial NeoplasmsCell Transformation NeoplasticUterine NeoplasmsFemaleSarcomabusinessPeritoneal NeoplasmOmentumHumanAmerican journal of obstetrics and gynecology
researchProduct

Mature teratoma of the uterine corpus with thyroid differentiation

2000

A case of a clinically silent mature teratoma of the uterine corpus is reported. A 55-year-old woman presented with multiple uterine leiomyomas. The discovery was incidental, because the patient was asymptomatic. Macroscopically, a colloid-hemorrhagic-looking nodule was present. Histologic and immunohistochemical studies showed that this tumor was a small thyroid mass. Key words:,

Calcitoninendocrine systemPathologymedicine.medical_specialtymedicine.medical_treatmentThyroid GlandHysterectomyThyroglobulinAsymptomaticPathology and Forensic MedicineImmunoenzyme TechniquesmedicineHumansUterine NeoplasmGynecologyHysterectomyUterine leiomyomabusiness.industryThyroidTeratomaCell DifferentiationNodule (medicine)General MedicineMiddle Agedmedicine.diseasemedicine.anatomical_structureUterine NeoplasmsFemaleThyroglobulinTeratomamedicine.symptombusinessPathology International
researchProduct